1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2016

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 147 pages

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2016’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects
- The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10
Therapeutics Development 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 12
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 13
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes 15
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 18
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes 20
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 21
A1M Pharma AB 21
Adrenomed AG 22
Am-Pharma B.V. 23
Angion Biomedica Corp. 24
Atox Bio Inc. 25
Cellmid Limited 26
Complexa, Inc. 27
DiaMedica Inc. 28
Digna Biotech, S.L. 29
DURECT Corporation 30
F. Hoffmann-La Roche Ltd. 31
G1 Therapeutics, Inc. 32
Ischemix, Inc. 33
Kringle Pharma, Inc. 34
NephroGenex, Inc. 35
NeuroVive Pharmaceutical AB 36
Noorik Biopharmaceuticals AG 37
Noxxon Pharma AG 38
Nyken B.V. 39
Orion Oyj 40
ProMetic Life Sciences Inc. 41
Quark Pharmaceuticals, Inc. 42
SBI Pharmaceuticals Co., Ltd. 43
Spherium Biomed S.L. 44
STATegics, Inc. 45
Thrasos Therapeutics Inc. 46
Torrent Pharmaceuticals Limited 47
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
A1M-001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
AB-103 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
adrecizumab - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
BB-3 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
CAB-101 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Cardiotrophin-1 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
Cell Therapy to Activate Wnt7b for Kidney Injury - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
CMX-2043 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
CXA-10 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
cyclosporine - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
DM-199 - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
DUR-928 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
HYPER-IL-6 - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
KP-100IT - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
levosimendan - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
MG-53 - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
MTP-131 - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
N-003 - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
NOXD-21 - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
NYK-1341 - Drug Profile 92
Product Description 92
Mechanism of Action 92
RandD Progress 92
PBI-4419 - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
Pyridoxamine Dihydrochloride - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
QPI-1002 - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
R-190 - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile 101
Product Description 101
Mechanism of Action 101
RandD Progress 101
Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 103
Product Description 103
Mechanism of Action 103
RandD Progress 103
RLS-003 - Drug Profile 104
Product Description 104
Mechanism of Action 104
RandD Progress 104
RO-6839328 - Drug Profile 105
Product Description 105
Mechanism of Action 105
RandD Progress 105
Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 106
Product Description 106
Mechanism of Action 106
RandD Progress 106
Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 107
Product Description 107
Mechanism of Action 107
RandD Progress 107
SP-15016 - Drug Profile 108
Product Description 108
Mechanism of Action 108
RandD Progress 108
STSE-15 - Drug Profile 109
Product Description 109
Mechanism of Action 109
RandD Progress 109
THR-184 - Drug Profile 111
Product Description 111
Mechanism of Action 111
RandD Progress 111
TRC-160334 - Drug Profile 113
Product Description 113
Mechanism of Action 113
RandD Progress 113
Acute Renal Failure (ARF) (Acute Kidney Injury) - Recent Pipeline Updates 114
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 138
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 139
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 140
Featured News and Press Releases 140
Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928 140
Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury 140
Dec 09, 2015: Ischemix Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound 141
Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study 141
Nov 10, 2015: Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision 142
Nov 04, 2015: DiaMedica Provides Corporate Update 142
Nov 04, 2015: NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin 144
Nov 02, 2015: Angion Biomedica to Present Clinical and Preclinical Data at the Upcoming American Society of Nephrology Conference in San Diego 144
Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials 145
Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury 145
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 146
Disclaimer 147

List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2016 11
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Development by Companies, H1 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2016 20
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1 2016 21
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H1 2016 22
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H1 2016 23
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H1 2016 24
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Inc., H1 2016 25
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H1 2016 26
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H1 2016 27
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H1 2016 28
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H1 2016 29
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H1 2016 30
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 31
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H1 2016 32
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Ischemix, Inc., H1 2016 33
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H1 2016 34
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H1 2016 35
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 36
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H1 2016 37
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noxxon Pharma AG, H1 2016 38
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken B.V., H1 2016 39
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H1 2016 40
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H1 2016 41
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 42
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co., Ltd., H1 2016 43
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed S.L., H1 2016 44
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H1 2016 45
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc., H1 2016 46
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 47
Assessment by Monotherapy Products, H1 2016 48
Assessment by Combination Products, H1 2016 49
Number of Products by Stage and Target, H1 2016 51
Number of Products by Stage and Mechanism of Action, H1 2016 53
Number of Products by Stage and Route of Administration, H1 2016 55
Number of Products by Stage and Molecule Type, H1 2016 57
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Recent Pipeline Updates, H1 2016 114
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2016 138
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2016 139

List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2016 11
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 48
Number of Products by Top 10 Targets, H1 2016 50
Number of Products by Stage and Top 10 Targets, H1 2016 50
Number of Products by Top 10 Mechanism of Actions, H1 2016 52
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 52
Number of Products by Routes of Administration, H1 2016 54
Number of Products by Stage and Routes of Administration, H1 2016 54
Number of Products by Molecule Types, H1 2016 56
Number of Products by Stage and Molecule Types, H1 2016 56

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Proteinuria is a result of an excess of serum proteins in the urine, which can led to renal damage. The most common cause of proteinuria is diabetes. Globally, development the arena of proteomics and ...

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Endometriosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Endometriosis Industry

October 2016 $ 4950

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.